|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 15, 2017 ) Ovarian malignancy is a sort of disease, which influences ovaries it causes fast and irregular increment of cell development in ovaries. The correct reason for disease is as yet obscure. An epithelial tumor, germ cell tumor and essential peritoneal carcinoma are sorts of ovarian malignancy. Normal indications incorporate weight in pelvis or lower back, changes in solid discharges, tiredness or low vitality and more continuous pee. In the greater part of the ovarian malignancy cases, growth won't be analyzed until the point that it has advanced to a propelled organize. Ovarian growth is one of most basic reason for tumor passings in lady. Along these lines requirement for advancement of the more viable medications in treatment of ovarian disease.
Increase in incidence of ovarian cancer worldwide is driving the ovarian cancer treatment market. According to WHO, an estimated 238,700 woman are diagnosed with ovarian cancer in 2012. The increase in older woman population, rising government funding and raising health care awareness able to grow ovarian cancer treatment market over the forecast period. According to ovarian cancer research fund alliance, the rate of prevalence of ovarian cancer is higher in woman between 55 to 66 years, many of the cancer foundations are funding to educate patients and healthcare professionals regarding symptoms and treatment options for ovarian cancer which may impact ovarian cancer market revenue growth positively over a forecast period. However, availability of generic drugs, lack of accurate diagnosis of ovarian cancer, and patient expiry of the key patented drugs like gemzar, taxol and paraplatin are expected to hamper the ovarian cancer treatment market.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-ovarian-cancer-treatment-market/#ulp-4H8Z4LpNMLEuOnnx
Ovarian cancer treatment market segmented on the basis of type of cancer, drug class, and stage
Based on type of cancer, ovarian cancer treatment market is segmented into
• Epithelial Ovarian Tumor
• Ovarian Germ Cell Tumor
• Ovarian Stomatal Tumor
• Primary Peritoneal Carcinoma
Based on drug class, ovarian cancer treatment market is segmented into
• Chemotherapeutic Agents
• Targeted Therapy Drugs
• Immune System Modulators
• Hormones
Based on distribution channel, ovarian cancer treatment market is segmented into
• Hospital Pharmacies
• Retail Pharmacies
• Others
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-ovarian-cancer-treatment-market/#ulp-c654SbFYO64MsOhu
Companies operating in ovarian cancer market investing in developing new drug therapies and finding newer molecular targets to treat ovarian cancer. For instance, Vintafolide an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co. and faltetuzumab a monoclonal antibody being investigated for the treatment of ovarian cancer this was developed by Morphotek, Inc. The introduction of new drug therapies like gene therapy, radiation therapy and targeted drug therapy are projected to improve ovarian cancer market revenue growth over forecast period. Global ovarian cancer market currently dominated by generic drugs and development of more effective drugs is challenging for market players. Some of the new drugs like avastin, lynparza and yondelis are approved in recent years to treat cancer and these drugs are slowly capturing market share.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-ovarian-cancer-treatment-market/#ulp-14mlyhjMGhVjZqa3
Geographically ovarian cancer treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the ovarian cancer treatment market due to rising number of ageing population. According to American cancer society, in U.S. about 22,440 women will receive a new diagnosis of ovarian cancer and about 14,080 women will die from ovarian cancer in 2017. Europe is largest market as the incidence rates of ovarian cancer is increased in the region.
Some of the players in ovarian cancer treatment market include Eli Lilly and Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Novogen Limited (Australia) , Aeterna Zentaris Inc. (U.S)., GlaxoSmithKline plc (UK), Boehringer Ingelheim GmbH (Germany) and F. Hoffmann-La Roche AG (Switzerland) to name a few.
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-ovarian-cancer-treatment-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Precision Business Insights
Sales
+1-866-598-1553
sales@precisionbusinessinsights.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
